Abstract Pyrosequencing was used to identify 133 isolates of clinically relevant non-dematiaceous yeasts. These included 97 ATCC strains (42 type strains), seven UAMH strains, and 29 clinical isolates. Isolates belonged to the following genera: Candida (18 species), Trichosporon (10), Cryptococcus (7), Malassezia (3), Rhodotorula (2), Geotrichum (1), Blastoschizomyces (1), and Kodamaea (1). Amplicons of a hyper-variable ITS region were obtained and analyzed using Pyrosequencing technology. The data were evaluated by a BLAST search against the GenBank database and correlated with data obtained by conventional cycle sequencing of the ITS1-5.8S-ITS2 region. Cycle sequencing identified 78.9% of the isolates to the species level. Pyrosequencing technology identified 69.1%. In 90.1% of all of the strains tested, the identification results of both sequencing methods were identical. Most Candida isolates can be identified to the species level by Pyrosequencing. Trichosporon species and some Cryptococcus species cannot be differentiated at the species level. Pyrosequencing can be used for the reliable identification of most commonly isolated non-dematiaceous yeasts, with a reduction of cost per identification compared to conventional sequencing.
Introduction
The increase in the population of severely immunocompromised patients has been associated with an increase of invasive fungal infections [1] . These infections remain a significant cause of morbidity and mortality in patients receiving chemotherapy for cancer or organ transplantation [1, 2] . The early detection of infection and identification of the etiologic agent permits the initiation of appropriate antifungal therapy, with reduced morbidity and increased possibility for survival [2, 3] .
Currently, more than 300 fungal species have been recognized as potential human pathogens [4] . Although most episodes of invasive fungal infection are still caused by Candica albicans, the proportion of infections caused by non-C. albicans species has risen substantially [5] . The widespread use of antifungal agents may have contributed to a shift in species distribution via the emergence of inherently resistant species as significant pathogens [3, 5] . The increasing importance of these isolates as causes of lifethreatening invasive fungal infections in high-risk patients has important diagnostic implications for the clinical laboratory. The timely identification of this increasing diversity of pathogens may be hampered by the limitations of current diagnostic methods. Conventional identification of yeasts relies upon a combination of morphological and biochemical features using tests that may require relatively long periods of incubation, are labor-intensive, and/or require subjective interpretation. Popular biochemical identification panels, such as API 20C AUX or VITEK ID-YST (bioMérieux, Durham, NC), may have limited databases, resulting in the misidentification of some isolates [6] [7] [8] [9] . Therefore, molecular methods offer an attractive, accurate, and rapid alternative for the identification of pathogenic yeast.
Several platforms have been evaluated for the identification of yeasts in which the rRNA genes are frequently the selected target [10, 11] . The availability of conserved and highly variable regions within the rRNA and its presence in multiple copies in fungal cells (Fig. 1 ) allows high sensitivity, as well as accurate molecular identification for most yeasts [10, 12, 13] .
Pyrosequencing technology is a relatively inexpensive, easy-to-use method that employs coupled enzymatic reactions to determine the nucleotide composition of a target DNA during the polymerization reaction, transforming the concomitant release of pyrophosphate into visible light [14] . In comparison to other methods, Pyrosequencing technology is limited to short fragments, but if the target is properly selected, it may provide enough information for the accurate identification of most clinically relevant yeasts. In this study, the conventional cycle sequencing (Sanger) method was compared to Pyrosequencing analysis for the identification of yeasts associated with human disease.
Materials and methods

Reference strains and clinical isolates
In the present study, 133 isolates were used. Tables 1 and 2 present the reference strains tested. Table 3 includes the clinical isolates tested. Lyophilized isolates were cultured on Sabouraud plates and incubated at 30°C for 3-5 days before genomic DNA extraction. For the remaining strains, genomic DNA was extracted directly from growth on Sabouraud agar slants. Biochemical assimilation tests were performed on some of the clinical isolates and reference strains that showed discrepant results between the ATCC identification and cycle sequencing results. All biochemical tests were performed using the API 20C AUX clinical yeast system, following the manufacturer's recommendations (bioMérieux, Durham, NC).
Cycle sequencing
Fungal DNA was extracted using the UltraClean Microbial DNA Isolation kit (MoBio Laboratories, Solana Beach, CA) following the manufacturer's recommendations for yeast genomic DNA extraction. Amplification of the ITS region (ITS1-5.8S-ITS2) was performed by using 1 pmol of the ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) primers [15] , 0.1 μg of extracted DNA, and ultrapure water to a final volume of 25 μl with PuReTaq Ready-To-Go PCR beads (GE Healthcare, Fairfield, CT). The DNA was denatured at 95°C for 5 min and then subjected to 35 cycles of amplification (95°C for 1 min, 55°C for 1 min, and 72°C for 1 min), followed by a 10-min extension at 72°C. The presence of PCR products was confirmed by gel electrophoresis. Purification of the PCR product was performed using a Microcon YM-100 centrifugation filter device (Millipore Corporation, Bedford, MA). Amplicons were then sequenced using the ITS1 and ITS4 primers and the Big Dye Terminator v1.1 cycle sequencing kit (Perkin- Fig. 1 Diagram of the ribosomal DNA cluster of fungi and location of the primers used for this study. The ribosomal DNA (rDNA) gene is a tandem array of at least 50-100 copies in the haploid genome of all fungi [7] . The diagram is based on one single gene repeat in the genome sequence of Candica albicans SC5314 [7, 20] . LSU=large ribosomal subunit; SSU=small ribosomal subunit; ITS1=intergenic transcribed spacer region 1; ITS2=intergenic transcribed spacer region 2. The small bars (ITS1, ITS4) refer to the approximate locations of the universal primers Elmer Applied Biosystems, Foster City, CA). Excess dye terminators were removed using CleanSeq magnetic particles according to the guidelines of the manufacturer (Agencourt, Beverly, MA). Fluorescence-based sequence analysis of the extension products was performed with the ABI 3100 genetic analyzer (Applied Biosystems/Hitachi, Foster City, CA). The resulting sequences were assembled using Lasergene SeqMan II software (DNA Star, Inc., Madison, WI), and compared to GenBank nucleotide sequences by using the BLASTN program (NCBI, Bethesda, MD). Sequences were aligned using the CLUS TAL W algorithm and phylogenetic trees were constructed C. neoformans ATCC 2505 corresponds to the type strain of Torula nasalis, synonym of C. neoformans var. neoformans [33] using the Lasergene MegAlign software (DNASTAR, Inc., Madison, WI).
Pyrosequencing analysis PCR was performed using PuReTaq Ready-To-Go PCR beads (GE Healthcare, Fairfield, CT) and primers included in the PyroMark™ Fungi ASR (Biotage, Charlottesville, VA). The PCR cycle included a 5-min initial denaturation and 35 cycles (95°C for 30 s, 58°C for 30 s, and 72°C for 30 s), followed by a 5-min extension at 72°C. PCR products were then confirmed by gel electrophoresis. Biotinylated amplicons were purified using streptavidincoated sepharose beads (GE Healthcare, Fairfield, CT) and Pyrogram reports generated were submitted as BLAST queries through GenBank (NCBI, Bethesda, MD). One inherent limitation of the Pyrosequencing technology is the determination of the number of incorporated nucleotides in homopolymeric regions. A non-linear light output resulting from the sequential incorporation of more than five to six identical nucleotides may require adjustments of the software algorithms used for the integration of light intensities [16] . Therefore, the visual interpretation of Pyrogram reports targeting these regions is recommended. Nonetheless, no "visual reading" adjustment was performed for any of the sequences obtained. Pyrogram reports that failed to provide an identifiable signal were annotated as "no signal" (Table 3) .
Results
For all of the species successfully identified within our samples, the sequencing of 20-30 bases of the selected ITS2 region (Fig. 1) was sufficient for differentiation. A summary of the concordant and discordant identification results on all of the reference strains is presented in Tables 1  and 2 , respectively. Results of the identification of the clinical isolates included in this study are presented in Table 3 . The cycle sequencing of two of the clinical isolates identified by biochemical methods as C. parapsilosis provided sequences homologous to the C. parapsilosis and C. orthopsilosis entries in GenBank. C. orthopsilosis is a newly defined species within the C. parapsilosis species complex [17] . However, differentiation within this species complex may be clinically irrelevant [17, 18] . Of the 133 clinical isolates and reference strains used in this study (43 species), a total of 119 (38 species) resulted in interpretable Pyrogram reports. No signal was generated for 14 strains (six species) and they correspond to isolates of C. lambica, Geotrichum candidum, Kodamaea ohmeri, C. lipolytica, C. zeylanoides 20393, and C. rugosa ATCC 96275. With the exception of Geotrichum candidum, PCR amplicons were successfully generated for these five species without any apparent reduction in yield or additional bands.
Our results using Pyrosequencing technology are presented in Table 4 and include the first 30 base pairs of all clinical isolates or reference strains used in this study. A total of 54 sequences that represent 38 different species are presented. All of these species were identified at the genus level and 27 of them at the species level. Neither method targeting the ITS region was able to identify at the species level the remaining 11 species. These species consist of all Trichosporon species (except T. pullulans), all isolates from the C. neoformans species complex, and some strains from the Cryptococcus luteolus/Bullera species group.
Discussion
In this work, we present an evaluation of Pyrosequencing technology as a tool for the identification of the most commonly isolated non-dematiaceous yeasts [5, 19] . The aim of the study was to compare the performance of this technology with the conventional cycle sequencing method. The targeted regions selected for these methods differ greatly in size, ITS1-5.8S-ITS2 (400-900 bp) for cycle sequencing versus a variable region of size limited by the [20, 21] . Those studies, however, were limited to not more than five different species. In our study targeting a different region, we were able to extend this approach and identify 27 different yeast species to the species level and 11 more to the genus level (Tables 1, 2, and 3) . Taking into consideration recent reports on the global trends of species distribution of invasive candidiasis [5, 22] , we estimate that this test is potentially capable of identifying 95% of all Candida clinical isolates to the species level. However, we found some limitations. Although our primer sets generate suitable PCR products from C. lipolytica, C. lambica, G. candidum, Kodamaea ohmeri, C. zeylanoides 20393, and C. rugosa ATCC 96275, identification by the Pyrosequencing method was not possible. Problems of annealing between the primers used for sequencing and the target rDNA sequence of these strains may explain the absence of signal when Pyrosequencing analysis is performed.
As described previously, this assay is unable to identify to the species level members of the Cryptococcus neoformans species complex, the Cryptococcus luteolus/Bullera species group, and most Trichosporon species previously grouped within Trichosporon beigelii [23] . The Cryptococcus neoformans species complex is now considered to be conformed of two species, C. neoformans (serogroups A and D) and Cryptococcus gattii (serogroups B and C) [24, 25] . However the clinical relevance of this differentiation has not been firmly established [25, 26] . If differentiation within the C. neoformans sp. complex is warranted, Pyrosequencing analysis or cycle sequencing of the rDNA will not adequately resolve these species, unless the sequencing of a "fast-evolving" region (such as the intergenic spacer region IGS) is used for this purpose [24, 27] .
A similar problem was observed within Trichosporon, a group that has recently undergone an extensive taxonomic re-evaluation. Sequencing the ITS region distinguishes three clades [23] . As shown in Table 4 , the Pyrosequencing results of species in Clade I (T. jiroveci, T. moniliforme, and T. mucoides) and Clade III (T. asahii, T. asteroides, T. coremiiforme, T. faecale, T. ovoides, and T. inkin) possess unique sequence signatures [23] . Our strain collection did not include any member of Clade II (e.g, T. domesticum, T. montevidense). However, using bioinformatics methods and sequences publicly available in GenBank, we found that T. pullulans yielded a Pyrogram report that was distinguishable from all clades. However, this species, now renamed Guehomyces pullulans [28] , should not be considered as a significant infectious agent in humans [29] .
The Cryptococcus laurentii species complex (15 species) can be divided into two phylogenetically distinct groups [30] . Based on the sequences determined by Takashima et al. [30] , our assay can differentiate among all the species currently included within phylogenetic group I (e.g., C. flavescens, C. aureus, C. laurentii). However, differences in the target annealing sequences of the sequencing primers (results not shown) prevents obtaining evaluable sequence data results from any member of phylogenetic group II (e.g., C. carnescens, C. peneaus, C. victoriae); these species do not appear to be clinically relevant and are primarily associated with marine or soil environments [30] .
One of the unanticipated outcomes of our study is the finding of discrepancies between the species designations of some of the ATCC isolates and the biochemical and molecular identification obtained by the methods employed here (Table 2 ). These discrepancies are especially evident with regard to the identification of the reference strains of Cryptococcus luteolus. The type strain C. luteolus ATCC 32044 was identified by both sequencing methods as C. luteolus. However, all other "C. luteolus" strains (ATCC 42279, ATCC 42280, ATCC 44440) were not identified satisfactorily at the species level by either sequencing (Table 3) . It is unclear if these isolates belong to the species C. luteolus.
One of the technical limitations of Pyrosequencing technology is the accurate resolution of long homopolymers. Unfortunately, the region targeted in our assay included some of theses sequences. Examples of these homopolymers are shown for the sequences obtained from C. terreus, M. sympodialis, C. catenulata, and C. neoformans (Table 4 ). The presence of homopolymers in the target region of C. neoformans increases the number of expected polymorphisms from two (according to cycle sequencing and GenBank databases) to five. Homopolymers are also present in the target sequence of Cryptococcus terreus, based on the current GenBank databases. Two polymorphisms are expected within this region. However, in two of the reference strains tested, the Pyrosequencing result obtained was different by one nucleotide deletion from either one of these polymorphisms.
It has been previously estimated that DNA polymerase in the presence of apyrase (the enzyme that eliminates excess deoxynucleotides during Pyrosequencing analysis), is capable of incorporating up to 10 identical adjacent nucleotides within a homopolymeric region [31] . However, in the experimental conditions employed, it seems that Pyrosequencing analysis may not reliably define the homopolymeric regions of more than three consecutive adenine bases in certain sequences (C. neoformans sequence, Table 4 ). However, adenine homopolymers may be resolved if they are located at the beginning of the region to be sequenced (C. catenulata sequence, Table 4 ). A condition that accentuates this problem is the excess of template (PCR product) that may enhance the nonsynchronized extension of DNA fragments. Some references suggest that, upon re-sequencing, it is possible to use a dispensation cycle in which the problem homopolymeric nucleotide is added twice in order to ensure complete polymerization and reduction of these non-synchronized DNA fragments [16] . However, the utility of this approach has to be determined empirically based on the sequence of the most frequent clinical isolates.
In four cases (Table 4 , isolates with 93% similarity), two unexpected nucleotide differences within the first 30 sequenced bases were observed in the following strains: M. sympodialis ATCC 96803, Cryptococcus gatti ATCC 32609, Cryptococcus neoformans ATCC 32045, and Cryptococcus neoformans ATCC 32268. In each case, BLASTN searches of the obtained sequences in GenBank resulted in correct identification with a 100% match. However, BLASTN obtained these results from portions of the submitted Pyrosequencing results excluding sections with problems of deletion or addition of bases within the homopolymeric regions.
It is important to emphasize that not all polymorphisms detected correspond to artifacts. In some instances, the intra-species variability observed was corroborated by conventional sequencing (e.g., C. haemulonii, C. parapsilosis, C. laurentii, C. luteolus, C. neoformans, C. terreus). Further optimization of the conditions tested for Pyrosequencing analysis (for instance, controlling the amount of template used per reaction) might reduce non-synchronized DNA polymerization associated with some of the sequence polymorphisms observed here.
The routine utilization of a molecular approach for the identification of clinically relevant yeasts will allow an accurate identification of the isolates and will provide a more reliable correlation of possible differences in clinical outcome virulence and epidemiology. The proposed identification approach provides an alternative tool for the differentiation between the closely related C. albicans and C. dubliniensis. C. dubliniensis was described as being more prevalent among immunocompromised and HIVinfected populations [32] .
In our experience, when compared to sequencing methods, the use of carbohydrate assimilation kits for the identification of yeasts is less reliable. When compared to conventional cycle sequencing, the implementation of Pyrosequencing analysis in the molecular identification scheme for yeasts is associated with a reduction in processing time of at least 4 h per batch. When compared to "in-house" sequencing assays, the reactive cost per reaction (including the cost of PyroMark Fungi ASR kit) is reduced by 13%. However, if the sample preparation buffers are prepared in the laboratory, the reactive cost per reaction is reduced by 46%.
The present approach will allow the identification to the species level of the majority of clinical yeast isolates (>95%). However, similar to the limitations of cycle sequencing of the ITS region, the Pyrosequencing assay evaluated here will not differentiate among species included within the Cryptococcus neoformans species complex and the Trichosporon species complex. Additionally, our Pyrosequencing approach was not able to obtain any sequence information for five species. However, these species may probably represent less than 1% of all clinical yeast isolates in the majority of clinical laboratories [5, 22] . They account for not more than 0.06% of the clinical isolates identified in our institution since 2001 (data not shown).
The workflow, workload, and financial resources available in each clinical laboratory will determine if DNA-based methods of identification could be used. Pyrosequencing technology represents a rapid and less expensive sequencing alternative that can be implemented in a clinical laboratory by technologists trained in conventional sequencing. The cost advantage of Pyrosequencing is maximized when a high volume of samples is processed; therefore, the standardization of targets and methodologies for the identification of different groups of bacteria, molds, and yeasts will favor the decision to incorporate this technology into clinical laboratory settings.
The present study demonstrates an alternative and relatively inexpensive approach for the sequencing-based identification of non-dematiaceous yeasts. A database of reference strains is provided (Table 4) that can be uploaded into the Pyrosequencing identification software (IdentiFire™ software) for the rapid implementation of this technology. The use of the database and the IdentiFire software will allow the identification to the species or genus level of the vast majority of non-dematiaceous yeasts of clinical significance.
